Bristol Myers and Pfizer said on Thursday they will start selling their blockbuster blood thinner, Eliquis, directly to ...

Pfizer, Inc. (NYSE:PFE) is one of the high-margin pharma stocks to buy now. Bristol-Myers Squibb Company (NYSE:BMY) and ...

Pfizer and Bristol Myers Squibb have launched a direct-to-patient program offering their blood thinner Eliquis at a 40% discount for cash-paying patients.  The list price for Eliquis (apixaban) is ...

The direct-to-consumer (DTC) platform – called Eliquis 360 Support – will offer Eliquis (apixaban) to patients who pay for ...

The reduced rate will still be almost 10 times the average monthly out-of-pocket costs paid by commercially insured patients.

Apixaban would still cost patients 9 times more through the Eliquis 360 Support program than with commercial insurance.

The health sector is witnessing notable developments. Bristol Myers and Pfizer are offering Eliquis at a discounted rate.

Bristol Myers' Reblozyl missed its primary goal in a Phase 3 anemia trial but showed positive secondary outcomes in ...

Recent developments in the health sector highlight diverse changes from drug pricing initiatives by Bristol Myers and Pfizer ...

Pfizer, in partnership with Bristol Myers Squibb, has launched a direct-to-patient sales strategy for Eliquis®, aiming to ...

Sino Biopharma will acquire LaNova Medicines, which has licensed cancer drugs for Merck and AstraZeneca, for $951 million.

Health-care companies fell after a lackluster round of earnings. Shares of medical-device maker Abbott Labs shares tumbled by more than 8% after it trimmed and narrowed its 2025 growth projections ...